title: Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients.
abstract: Peripheral T cell lymphoma (PTCL) is a heterogeneous group of aggressive lymphomas with poor prognosis. Elderly (age ≥ 65years) patients generally have impaired bone marrow function, altered drug metabolism, comorbidities, and poor functional status. Thus, treatment of elderly patients with relapsed or refractory PTCL remains a challenge for clinicians. A recent study disclosed that pralatrexate has a synergistic effect in combination with bortezomib. Weekly pralatrexate and bortezomib were administered intravenously for 3 weeks in a 4-week cycle. Of 5 patients, one achieved complete response after 4 cycles which has lasted 12 months until now. Another patient attained partial response after 2 cycles. Only 1 patient experienced grade 3 thrombocytopenia and neutropenia. Two patients suffered from grade 3 mucositis. Combination therapy with pralatrexate and bortezomib may be used as a salvage therapy for relapsed or refractory PTCL in the elderly with a favorable safety profile.
authors.affiliation: Department of Hematology and Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea .
authors.forename: Seung-Shin
authors.identifier: 0000-0002-8174-6861
authors.initials: SS
authors.lastname: Lee
authors.affiliation: Department of Hematology and Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea .
authors.forename: Sung-Hoon
authors.identifier: 0000-0002-3753-5282
authors.initials: SH
authors.lastname: Jung
authors.affiliation: Department of Hematology and Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea .
authors.forename: Jae-Sook
authors.identifier: 0000-0003-3078-5024
authors.initials: JS
authors.lastname: Ahn
authors.affiliation: Department of Hematology and Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea .
authors.forename: Yeo-Kyeoung
authors.identifier: 0000-0001-5447-4285
authors.initials: YK
authors.lastname: Kim
authors.affiliation: Department of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun, Korea .
authors.forename: Min-Seok
authors.identifier: 0000-0001-6649-4742
authors.initials: MS
authors.lastname: Cho
authors.affiliation: Department of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun, Korea .
authors.forename: Seung-Yeon
authors.identifier: 0000-0003-4067-028X
authors.initials: SY
authors.lastname: Jung
authors.affiliation: Department of Hematology and Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea .
authors.forename: Je-Jung
authors.identifier: 0000-0002-4635-5697
authors.initials: JJ
authors.lastname: Lee
authors.affiliation: Department of Hematology and Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea .
authors.forename: Hyeoung-Joon
authors.identifier: 0000-0002-0998-1090
authors.initials: HJ
authors.lastname: Kim
authors.affiliation: Department of Hematology and Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea .
authors.forename: Deok-Hwan
authors.identifier: 0000-0003-2830-9889
authors.initials: DH
authors.lastname: Yang
mesh_terms: D000368:Aged; D000630:Aminopterin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000069286:Bortezomib / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006801:Humans; D016411:Lymphoma, T-Cell, Peripheral / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D009364:Neoplasm Recurrence, Local; D009503:Neutropenia / Q000209:etiology; D000072078:Positron Emission Tomography Computed Tomography
chemical_list: C418863:10-propargyl-10-deazaaminopterin; D000970:Antineoplastic Agents; D000069286:Bortezomib; D000630:Aminopterin
keywords: Bortezomib; Elderly; Peripheral T Cell Lymphoma; Pralatrexate